Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss XLRP Full 12-Month Data from Highest Dose Groups and 24-Month Data from a Subset of Group 4 Patients of its Ongoing Phase 1/2 Clinical Trial
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 05, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today
View HTML
Toggle Summary AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
View HTML
Toggle Summary AGTC Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials
-Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021- ALACHUA, Fla. and CAMBRIDGE, Mass. , May 03, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company
View HTML
Toggle Summary AGTC Announces Data to be Presented from the Ongoing XLRP and Achromatopsia Clinical Trials at the ARVO 2021 Virtual Annual Meeting
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , April 29, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Departure of Chief Scientific Officer
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , April 26, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC licenses Promoter Technology to SparingVision SAS
-Technology To Be Incorporated In Multiple SparingVision SAS Programs- ALACHUA, Fla. and CAMBRIDGE, Mass. , April 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene
View HTML
Toggle Summary TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program
- AGTC Transfers Clinical Trial Materials and Phase 1/2 Data To TeamedON - ROCKVILLE, Md. , April 13, 2021 (GLOBE NEWSWIRE) -- TeamedOn International, Inc. , a biotechnology company dedicated to advancing gene therapies for rare diseases, including ophthalmic indications, and Applied Genetic
View HTML
Toggle Summary AGTC to Participate in Upcoming Virtual Biotech Corporate Access Day and Cell and Gene Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , March 31, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces New Initiatives To Enhance The Patient Journey In Its XLRP Trials
-AGTC’s deep commitment to the patient voice drives solutions to support patient access to information and to improve the experience of patients participating in clinical trials- GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , March 25, 2021 (GLOBE NEWSWIRE) -- Applied Genetics Technologies Corporation
View HTML
Toggle Summary AGTC to Present at the Gene Therapy Patient Engagement Summit, Held Virtually, March 24, 2021
-AGTC will highlight the value of the patient voice in gene therapy development- GAINESVILLE, Fla. and CAMBRIDGE, Mass. , March 18, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus
View HTML
Visionary science for life changing cures.